DWTX

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor T

PRE 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX", "Dogwood" or "the Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced FDA acceptance of an Investigational New Drug ("IND") application for its development candidate SP16, administered intravenously ("IV"), for the treatment of chemotherapy-induced pain and perip

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

10-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. "The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year," said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key Highlights In Decem

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

DEF 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

 - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain ("HALT-CINP") trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026. "If the HALT-CINP study is successful, Halenuron® would represent a new therapeutic agent for tre

EFFECT - Dogwood Therapeutics, Inc. (0001818844) (Filer)

PRE 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

S-3 - Dogwood Therapeutics, Inc. (0001818844) (Filer)

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

424B5 - Dogwood Therapeutics, Inc. (0001818844) (Filer)

Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules  ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering (the "Registered Offering") and a concurrent private placement (the "Private Offering" and, together with the Registered Offering, the

S-8 - Dogwood Therapeutics, Inc. (0001818844) (Filer)

- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines - ATLANTA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announces positive results from an interim analysis of 97 patients who had completed treatment in the ongoing Halneuron® Phase 2b chemotherapy induced neuropathic pain ("CINP") study. The independent statistical review

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)